Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning
Clinical Gastroenterology and Hepatology · 2025-02 · 23 (3) · 454-468
DOI: 10.1016/j.cgh.2024.06.050 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Gastroenterology and Hepatology, 2025-02. Verfasst von David I Fudman und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: david.fudman@utsouthwes…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Biological Products, Biological Factors. Die Arbeit wurde bisher 74-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases, Leona M. and Harry B. Helmsley Charitable Trust.
Abstract (Originalsprache)
The therapeutic armamentarium for management of inflammatory bowel diseases has expanded dramatically in the last 5 years, with the introduction of several medications with different mechanisms of action. These include the oral small molecule drugs Janus kinase inhibitors (including upadacitinib, approved for Crohn's disease and ulcerative colitis [UC], and tofacitinib, approved for UC) and sphingosphine 1-phosphate receptor modulators (ozanimod and etrasimod, both approved for UC), and biologic agents, such as selective interleukin-23 antagonists (risankizumab approved for Crohn's disease, and mirikizumab approved for UC). The efficacy and safety of these therapies vary. In this review, we discuss practical use of these newer advanced therapies focusing on real-world effectiveness and safety data, dosing and monitoring considerations, and special situations for their use, such as pregnancy, comorbid immune-mediated disease, use in hospitalized patients with acute severe UC, and in the perioperative setting. We also propose our approach to positioning these therapies in clinical practice, relying on careful integration of the medication's comparative effectiveness and safety in the context of an individual patient's risk of disease- and treatment-related complications and preferences.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, Texas. Electronic address: david.fudman@utsouthwestern.edu.
- Division of Gastroenterology, Palo Alto Medical Foundation, Palo Alto, California.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona.
- Division of Gastroenterology, Department of Medicine, UC San Diego, La Jolla, California; Division of Biomedical Informatics, Department of Medicine, UC San Diego, La Jolla, California.
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
- Leona M. and Harry B. Helmsley Charitable Trust
- Pfizer
- National Institutes of Health
Zitieren
APA
Fudman, D. I., McConnell, R. A., Ha, C., & Singh, S. (2025). Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning. Clinical Gastroenterology and Hepatology, 23(3), 454-468. https://doi.org/10.1016/j.cgh.2024.06.050
Vancouver
Fudman DI, McConnell RA, Ha C, Singh S. Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning. Clinical Gastroenterology and Hepatology. 2025;23(3):454-468. doi:10.1016/j.cgh.2024.06.050
BibTeX
@article{Fudman2025,
author = {Fudman, David I and McConnell, Ryan A and Ha, Christina and Singh, Siddharth},
title = {Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning},
journal = {Clinical Gastroenterology and Hepatology},
year = {2025},
volume = {23},
number = {3},
pages = {454--468},
doi = {10.1016/j.cgh.2024.06.050}
}
EUVIMED